Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Epilepsy

Clinical and regulatory intelligence for Epilepsy with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 11
Catalysts: 0
Assets: 7

Relevant assets

Relevant companies

BIOCODEX SA →

UCB Biopharma →

Recent signals(11)

ClinicalAugust 13, 2026

BRAVE Study Investigates Adenosine Pathway in Drug-Resistant Epilepsy and SUDEP Risk

The BRAVE study, sponsored by Hospices Civils de Lyon, is currently investigating alterations in adenosine receptors (ARs) within the brainstem of patients with drug-resistant epilepsy. This trial specifically examines the relationship between these receptor alterations and respiratory dysfunction,

RegulatoryAugust 10, 2026

UCB's Fintepla NDA Supplement Receives FDA Application Status

UCB's NDA supplement for Fintepla (fenfluramine hydrochloride) has received application status from the FDA.

CompetitiveAugust 4, 2026

iVEAcare Neuromodulation System Study for Drug-Resistant Epilepsy Underway

A feasibility study is assessing the safety and performance of the iVEAcare Neuromodulation System in drug-resistant epilepsy patients.

RegulatoryJuly 27, 2026

FDA Accepts Supplemental Application for Diacomit (Stiripentol)

The FDA has accepted a supplemental application for Diacomit (stiripentol) submitted by Biocodex SA.

ClinicalJuly 27, 2026

UCB Biopharma's Staccato Alprazolam Trial Targets Prolonged Seizures in Patients 12 and Older

A study is underway to evaluate the efficacy and safety of Staccato alprazolam in terminating seizure episodes in patients aged 12 and older.

RegulatoryJuly 26, 2026

FDA Accepts Supplemental NDA for Diacomit (Stiripentol) by Biocodex

The FDA has accepted a supplemental NDA for Diacomit, an epilepsy treatment containing stiripentol.

ClinicalJuly 26, 2026

Study on Predictors of Drug-Resistant Epilepsy in Children Initiated

A prospective cohort study is underway to identify predictors of drug-resistant epilepsy in children using machine-learning models.

RegulatoryJuly 20, 2026

FDA Accepts Supplement for FINTEPLA (Fenfluramine) by UCB

The FDA has accepted a supplemental application for FINTEPLA, an epilepsy treatment containing fenfluramine hydrochloride.

ClinicalJuly 5, 2026

Study on Social Feedback's Impact on Intracranial EEG in Epilepsy Patients

A clinical trial is assessing how social feedback influences neural recordings in epilepsy patients during surgery.

RegulatoryJuly 4, 2026

FDA Accepts Supplement for DIACOMIT (Stiripentol) by BIOCODEX SA

The FDA has accepted a supplemental application for DIACOMIT (Stiripentol) submitted by BIOCODEX SA.

ClinicalJuly 2, 2026

Eisai's Fycompa Injection Safety Study for Epilepsy Underway

Eisai is conducting a study to evaluate the safety of Fycompa injection in patients with partial-onset seizures and primary generalized tonic-clonic seizures.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.